You are here:

alendronic acid (Binosto)

Advice

following an abbreviated submission

alendronic acid effervescent tablets (Binosto®) is accepted for restricted use within NHS Scotland.

Indication under review: Treatment of postmenopausal osteoporosis. 

SMC restriction: for use in patients who are unable to swallow tablets where alendronic acid is the appropriate treatment choice.

Alendronic acid 70mg effervescent tablets have demonstrated bioequivalence to alendronic acid 70mg tablets. The effervescent tablet formulation provides an alternative for patients who cannot swallow tablets. It is more expensive than generic alendronic acid tablets but is similar to the cost of existing oral solutions. 

Drug Details

Drug Name: alendronic acid (Binosto)
SMC Drug ID: 1137/16
Manufacturer: Internis Pharmaceuticals Ltd
Indication: for the treatment of postmenopausal osteoporosis. Binosto 70 mg reduces the risk of vertebral and hip fractures.
BNF Category:
Sub Category: 6.6 Drugs affecting bone metabolism
Submission Type: Abbreviated Submission
Status: Restricted
Date Advice Published: 11 April 2016

Back